Aggregating epidemiological evidence: comparing two seminal EMF reviews

Mike J. O’Carroll¹ & Denis L. Henshaw²

¹University of Sunderland, Garden House, Welbury, Northallerton, DL6 2SE, UK
²H H Wills Physics Laboratory, University of Bristol, Tyndall Avenue, Bristol, BS8 1TL, UK

Keywords: risk, electric and magnetic fields, EMFs, health effects, statistical significance, aggregating evidence, childhood leukaemia, adult leukaemia, brain cancer

Running title: Comparing EMF reviews

Abstract

Two seminal reviews (IARC 2002, CDHS 2002) of possible health effects from power-frequency EMFs reached partly different conclusions from largely similar epidemiological evidence. These differences can have an impact on precautionary policy.

We examine the statistical aggregation of results from individual disparate studies. Without consistent exposure metrics, the advantage of meta-analysis and pooling to estimate magnitude of effect and confidence limits is lost. However, counting positive results and statistically significant results yields important information with p-values reflecting the overall strength of evidence.

Representative results from 33 independent adult leukaemia studies tabled by IARC yielded 23.5 positives ($p \approx 0.01$) and 9 significant-positives ($p < 10^{-7}$). From 43 representative results from CDHS, there were 32 positive ($p < 0.001$) and 14 significant-positives ($p < 10^{-12}$). There were no significant-negative results in either list. Results for adult brain cancer gave a similar, but less clear, message.

Results for childhood leukaemia suggests they are not stronger, numerically, than those for adult leukaemia, and that formal pooling of coherent studies shows a stronger association than aggregating all the studies.

CDHS did not note the number of significant positives, but noted the meta-analytic summary and the number of positives, forming a view about the strength of these findings. IARC shows no evidence of considering the aggregation of results other than subjectively. It considered individual studies but this led to a tendency to fragment and dismiss evidence which is intrinsically highly significant. We make recommendations for future reviews.
1. Introduction

The key purpose behind this paper is to try to understand how two seminal reports from major health bodies, reviewing the possible health effects of exposure to power frequency electric and magnetic fields (EMFs), reached different conclusions from what was largely the same body of evidence. While there are constitutional and procedural differences between the review bodies, we have focused on a striking difference in how they went from critical review of the many individual studies of EMF health effects to a summative assessment of the overall weight of evidence.

The review bodies were the International Agency for Research on Cancer (IARC), an agency of the World Health Organization, and the California EMF Program team of the California Department of Health Services (CDHS). Both published the reports of their reviews of EMFs and health in 2002. Both rated power-frequency EMFs as “possibly carcinogenic to humans” (the IARC class 2B), on the basis of epidemiological evidence relating to childhood leukaemia. In respect of all other cancers IARC concluded the epidemiological evidence was “inadequate”, whereas CDHS concluded it was “limited” for four other health outcomes, including two cancers. The “limited” assessment supports class 2B for the agent.

There have been other reviews, before and since 2002. For example, the NRPB reviews in the UK have consistently recognised the possibility of cause of cancer, but did not use a formal classification system for assessment. Some reviews never reached publication, for example in the US the NCRP review in 1995, though its conclusions were leaked. The subject of power-frequency EMFs has been controversial. In the 1990s there were calls to halt research funding on the basis that any potential risk had been dismissed. However, the evidence of adverse health effects has persisted to the point that precaution against exposure to EMFs is now being considered.

The US National Institute of Environmental Health Sciences (NIEHS) EMF-Rapid programme concluded in 1998 that the evidence for both childhood and adult leukaemia supported a 2B classification. Two key pooled analyses, Ahlbom et al. (2000) and Greenland et al. (2000) reinforced concerns, showing, by statistical aggregation, that the fragmented findings for childhood leukaemia became stronger when pooled, the former revealing a 2-fold increase in risk associated with time-weighted average magnetic field exposures above 0.4 µT, the latter a 1.7-fold increase above 0.3 µT.

When IARC made its formal 2B classification in 2002 against this background, a basis was set for precautionary policy which is under development in several countries and in the WHO. Policy based on the risk of childhood leukaemia alone tends to be limited, because the normal incidence is comparatively rare and the attributable risk very small. The question of additional risk of other diseases then becomes important. Hence the California review, by recognising five health outcomes corresponding to the 2B classification, challenges the limitation of proportionate precautionary measures to those of very low cost.

An understanding of the differences between these seminal reviews is therefore important to the present development of precautionary policy for EMFs.
2. The two seminal EMF health reviews of IARC and CDHS

Both IARC (2002) and CDHS (2002) evaluated the possible risks to public health from EMFs at supply frequency. CDHS considered only power-frequency EMFs, whereas IARC considered other frequencies but specifically assessed power frequency (or ELF). IARC assessed carcinogenic risk whereas CDHS assessed both carcinogenic and other health outcomes. Nevertheless the two reviews had a large area of common ground in the body of evidence relating to power-frequency fields and various cancer outcomes.

The formative work for IARC 2002 was carried out at a Working Group meeting in June 2001. The CDHS programme extended over several years with Consultation Draft 3 published in April 2001. IARC (2002) did not refer to recent CDHS drafts but did refer to an earlier progress review (Neutra et al. 1996). The final report CDHS 2002 referred to IARC (2001 in press) and particularly addressed the question of their differing conclusions.

IARC (2002) listed some 800 references, covering both ELF (mainly power-frequency) and static fields. CDHS listed some 400 references (ELF only).

The IARC classification system formally combines assessments of evidence in humans (essentially epidemiology) and evidence in animals. Both reviews were agreed in assessing the evidence in animals as “inadequate”. A particular difficulty in relation to childhood leukaemia is that animal studies could be considered inappropriate since there is no animal model for acute lymphoblastic leukaemia, the common leukaemia type in children. Both reviews were agreed in assessing the evidence in humans in relation to childhood leukaemia as “limited”, and hence were led by the formal classification system to the overall IARC 2B assessment.

CDHS 2002 uses another formal system of assessment, a “qualitative Bayes” approach, which is a central feature of the review and an interesting innovation. However, for the purpose of comparison, they also provide assessments on the IARC classification system. The five health outcomes identified by CDHS as each warranting IARC 2B classification of EMFs were childhood leukaemia, adult leukaemia, adult brain cancer, miscarriage and amyotrophic lateral sclerosis (ALS), a form of motor neurone disease.

This paper compares the bases of epidemiological evidence in the two reviews, specifically for adult leukaemia and adult brain cancer. Considering the aggregate value of the evidence should have some bearing on its formal assessment and should illuminate the differences in the reviews’ conclusions.

3. Statistical aggregation of disparate findings from epidemiological studies

It is not unusual to find a range of reasonably independent epidemiological studies, each with its limitations and statistically weak findings, but nevertheless with an overall tendency to indicate a possible effect. One way of aggregating the evidence from such studies is by meta-analysis or pooling, which may be defined in slightly different ways.
This has the advantage of estimating the magnitude of an effect and providing confidence limits from the aggregate evidence. Such estimates are most meaningful when aggregating on a like-for-like basis with regard to exposure metric, specificity of cases, relevant subsets of population and study methods.

Sometimes the evidence is more disparate, so that only limited numbers of similar studies can be pooled to give very meaningful estimates of parameters such as risk estimates representing magnitude of a possible effect. For example, in the context of EMF, the majority of studies have been concerned with the effects of exposure to magnetic fields. Studies may vary according to type of exposure (residential, occupational), subsets of population (gender, race, age, susceptibility), exposure metric or proxy (measurement, proximity, job title, average, peak), or risk measure (Odds Ratio or Standardised Incidence Rate) and so on.

While taking account of the caveats and qualifications relating to significance and hypothesis testing, as discussed for example in Rothman and Greenland, 1998, chapter 12, it is nevertheless possible to make some assessment of the strength of aggregate disparate evidence. This may be useful in supporting formal assessment of evidence, in comparing different aggregate sets of studies and in comparing different conclusions reached by review bodies.

This paper illustrates two simple methods of aggregation: counting numbers of positive findings and counting numbers of statistically significant positive findings. The more disparate the studies and findings considered, the blunter the implied hypothesis, whose negation is the null hypothesis under examination. For example, aggregating both residential and occupational studies implies a hypothesis that both “exposures” are causal risk factors for the specified disease. That is more demanding than a choice of either sharper hypothesis with a more consistent exposure. It is not the purpose of this paper to provide a formal analysis of sharp, blunt and compound hypotheses.

4. General comparison of evidence bases for adult leukaemia

IARC selected and tabled results including OR or SIR with CI data from 37 (33 independent) human epidemiology studies for adult leukaemia, and CDHS did so for 43. However, despite the reviews’ publication in the same year and despite the common reference to previous reviews, these sets of studies had surprising differences. Both reviews identify residential and occupational studies specific to adult leukaemia. IARC’s 37 included 6 residential whereas CDHS’s 43 only included 2 residential.

The 43 studies listed by CDHS are derived principally from the same reference source (Kheifets et al. 1997a). Of the 41 occupational studies, 17 are included in the IARC tables for adult leukaemia, 18 are not (of which 5 are however listed in IARC’s references), and the other 6 refer to similar studies by the same authors (e.g. with different dates), so may overlap.

Of the 32 occupational studies considered by IARC, after deducting 17 common and 6 similar studies, there remain 9 which are not in CDHS. Of the 6 residential studies listed by IARC (Table 25), only one (Severson 1998) is listed in the CDHS table for adult leukaemia.
The second residential study listed by CDHS is Wertheimer & Leeper 1982, which is not in IARC’s Table 25.

Of the 41 occupational studies listed by CDHS, there are two sets of multiple studies from the same source (three from Theriault et al. 1994 and two from Tynes et al. 1994; the bibliography lists two studies by Theriault et al. 1994 and two by Tynes et al. 1994). IARC lists three studies by Theriault et al. 1994, in Quebec, France and Ontario, and a fourth updating paper by Miller et al. 1996.

Both reviews take account of the caveats and qualifications in the various studies, and comment on their shortcomings, and draw on previous reviews in that respect. Neither review body is unaware of these qualitative considerations. Both are aware of the potential for bias and confounding and both address this specifically. Their conclusions however do give different weight to the human epidemiology studies in aggregate; this was the main observation in the CDHS comparison of the two reviews and reasons for their differences. This paper examines the statistical aggregation of evidence for the two reviews’ sets of studies.

5. Statistical aggregation of the CDHS set of adult leukaemia studies

In the CDHS set of adult leukaemia studies, there are similar relative risks or odds ratios for the residential and the occupational studies. While the exposures are disparate between residential and occupational studies, the strengths of association are similar. The summary table (fig. 8.1.1, page 121) combined one odds ratio (OR) result, with its 95% confidence interval (CI), from each of the 43 studies. Taking all 43 studies together, the meta-analytic summary was OR = 1.2 with CI = 1.12 - 1.24. (The CI was given in the draft 3 CDHS report but not in the final version). The summary notes that 29 had OR > 1 with p ≤ 0.01. That is, in aggregate the occurrence of positive results is statistically significant at a 99% confidence level. The selection of studies and of results from each study was derived principally from a previous reviewer (Kheifets et al.) and adopted by CDHS in preference to introducing their own selection. Hence the 43 results were taken as independent.

There were 6 results with OR = 1.00 within the truncation of the report. It is more appropriate to count such results as half negative and half positive, as that would give an unbiased estimate of the true value (50%) under the null hypothesis. Some studies in other sets have a coarser truncation to only one decimal place, with a more substantial truncation bias. While CDHS deploy what they call the sign test, they use a biased version of it which substantially understates the strength of evidence. In the above, including results with OR = 1.00 as half positive and half negative gives 32 positive results with p < 0.001, which is highly significant.

A much stronger statistical observation, not made by CDHS, is the number of significant positive results. They are results with 95% confidence intervals wholly above 1. Although the intervals may be based on two-sided p-values of 0.05, they invariably correspond to one-sided values of 0.025 for positive results. There are no significant-negative results in the reviewers’ lists for adult leukaemia. Whether the confidence limits have been calculated by a fully frequentist approach or by inference from sample to whole population, each occurrence of a significant-positive result will have, by the same statistical model as used in
the calculation, a probability $p < 0.025$.

There are 9 such occurrences, that is strictly significant-positive results from the 43 listed results, with lower confidence limit (CL) strictly $> 1$, plus 5 results with lower CL = 1.00, and no significant negatives. The significance boundary is different from the 50-50 split for simple positives, so that a marginal occurrence with lower confidence limit equal to 1 might now be counted as with $p = 0.025$ for the occurrence. Although the truncation may slightly bias an estimate of a true value under a null hypothesis, it will be a good approximation as long as the truncation error (here 0.005) is small compared with OR - 1, which it is.

Therefore, such marginal occurrences of significant-positives should reasonably be fully counted as instances with $p = 0.025$, giving 14 in all. As long as these results are independent, and considering only random error and not bias or confounding (which have been addressed in the reviews), the probability of 14 such results out of 43 can be calculated by the cumulative binomial distribution as about $10^{-12}$, which is extremely significant. Even that is conservative, for most of the separate p-values will be strictly less than 0.025. Even if the 5 marginal occurrences were only counted as halves there would still be 11.5 occurrences with aggregate p-value approximately $10^{-8}$, which is still extremely significant, although that would not be the appropriate form of counting.

Although CDHS did not note the number of significant positives, they did note the meta-analytic summary and the number of positives, and formed a view about the strength of these findings which led them to give them greater weight than, seemingly, did IARC. The aggregation of the studies considered by CDHS is summarised in Table 1.

**Table 1.** Aggregation of the adult leukaemia (AL) studies considered by CDHS (2002).

<table>
<thead>
<tr>
<th>CDHS / AL (1 per study)</th>
<th>No. of ORs</th>
<th>Positives</th>
<th>p-value for positives</th>
<th>Significant Positives</th>
<th>p-value for sig-pos*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Residential</td>
<td>2</td>
<td>2</td>
<td>0.25</td>
<td>1</td>
<td>0.049</td>
</tr>
<tr>
<td>occupational</td>
<td>41</td>
<td>30</td>
<td>0.002</td>
<td>13</td>
<td>$1 \times 10^{-11}$</td>
</tr>
<tr>
<td>Total</td>
<td>43</td>
<td>32</td>
<td>0.001</td>
<td>14</td>
<td>$1 \times 10^{-12}$</td>
</tr>
</tbody>
</table>

*One-sided, $p < 0.025$

6. **Statistical aggregation of the adult leukaemia results chosen by IARC.**

IARC discusses a range of adult leukaemia studies and selects 37 studies with ORs or SIRs with CI data for summary description in Tables 25, 29 and 30. The Tables list some 176 results including multiple results from single studies, and including both high and low exposure categories. These are not independent, e.g. some are totals of other results for sub-types of leukaemia, so aggregating them by cumulative binomial distribution would not be valid.

It is surprising however, not least since low exposure categories may dilute the overall apparent significance, that simply lumping all the IARC-reported results together (omitting only base or reference levels) would show an apparent strong aggregation, with 111.5
positive results and 31 significant-positives out of the 176. If the results were independent, those counts would have p-values of 0.0003 and $3 \times 10^{-15}$ respectively, which we note for reference when considering the effect of selecting more independent subsets of results. Truncated marginal ORs or lower CLs are again counted as explained above for CDHS.

In order to obtain a more independent set of results for aggregation, select at most one representative result from each study, using a common set of selection criteria:

- Omit studies and results which do not record either the OR or the CI.
- Where there are multiple results for sub-types of leukaemia, select only the total or “all leukaemias” results, if available, so that sub-type results are not repeated. While this loses specificity, and so may dilute findings, the alternative would be to apply the same specificity throughout all selected studies. Likewise, take Theriault et al. 1994 combined cohort results, not the separate ones for France, Quebec and Ontario.
- Where there are separate results tabled for different exposure bands from the same study, select only the highest band, so that the most relevant test to detect an effect (positive or negative) is used. That will typically be with a cut point at 0.2 µT, which is lower than the principal categories of Ahlbom et al. and Greenland et al. for childhood leukaemia.
- Where there are separate results for different occupations, select the results for the occupation likely to be most exposed, and if that is not known, select the most populous result.
- Where there are different results for males and females, and no combined gender results, select the most populous results (usually males). While this loses specificity, the alternative would be to seek separate results for males (or females) throughout all selected studies.
- Where the choice remains ambiguous on the above criteria, and yet would make a difference, select an appropriate balance, e.g. half positive and half negative.
- Where two papers from the same source draw on the same data set but analyse it in different ways, select only one result using the above criteria.

We emphasise that these are our selection criteria. They were not applied by either of the review bodies.

Such a selection leads to the summary in Table 2. While still showing highly significant results, selection has moderated, not exaggerated, the strength of the crudely aggregated original data. For example, the results would have been slightly stronger if the significant-positive finding by Alfredson et al. (1996) for 10 lymphocytic leukaemia cases for ages 20 - 64 years were included; while some significant information was lost, the objective selection criteria chose 20 all-leukaemia all-ages cases instead.
Table 2. Aggregation of studies of adult leukaemia in IARC (2002) on the basis of selection criteria to identify one representative result per study

<table>
<thead>
<tr>
<th>IARC / AL (1 per study)</th>
<th>No. of ORs</th>
<th>Positives</th>
<th>p-value for positives</th>
<th>Significant positives</th>
<th>p-value for sig-pos</th>
</tr>
</thead>
<tbody>
<tr>
<td>Residential cohort</td>
<td>5</td>
<td>3.5</td>
<td>0.19 - 0.5</td>
<td>2</td>
<td>0.0059</td>
</tr>
<tr>
<td>Occupational</td>
<td>17</td>
<td>11.5</td>
<td>0.07 - 0.17</td>
<td>4</td>
<td>0.0007</td>
</tr>
<tr>
<td>Case-control occupational</td>
<td>11</td>
<td>8.5</td>
<td>0.03 - 0.11</td>
<td>3</td>
<td>0.002</td>
</tr>
<tr>
<td>Total</td>
<td>33</td>
<td>23.5</td>
<td>0.007 - 0.018</td>
<td>9</td>
<td>1 x 10^{-7}</td>
</tr>
</tbody>
</table>

Further selection may be made according to the additional criteria:

- Omit results which give low cumulative exposures in µT-years, typically below average 0.2 µT.
- Omit occupational studies which give no estimate of exposure.

This gives the results in Table 3.

Table 3. Aggregation of studies of adult leukaemia in IARC (2002) on the basis of additional selection criteria to identify results with comparable exposures

<table>
<thead>
<tr>
<th>IARC / AL (select results)</th>
<th>No. of ORs</th>
<th>Positives</th>
<th>p-value for positives</th>
<th>Significant positives</th>
<th>p-value for Sig-Pos</th>
</tr>
</thead>
<tbody>
<tr>
<td>Residential Cohort</td>
<td>4</td>
<td>3.5</td>
<td>0.06 - 0.31</td>
<td>2</td>
<td>0.0036</td>
</tr>
<tr>
<td>Occupational</td>
<td>4</td>
<td>4</td>
<td>0.0625</td>
<td>2</td>
<td>0.0036</td>
</tr>
<tr>
<td>Case-control occupational</td>
<td>5</td>
<td>4</td>
<td>0.1875</td>
<td>2</td>
<td>0.0059</td>
</tr>
<tr>
<td>Total</td>
<td>13</td>
<td>11.5</td>
<td>0.002 - 0.01</td>
<td>6</td>
<td>3.6 x 10^{-7}</td>
</tr>
</tbody>
</table>

As would be expected, the effect of our selection is to reduce numbers of results admitted, and to reduce p-values, while increasing the percentage both of positive results and of significant-positive results.

IARC also summarises 4 studies of electric fields (EF) and adult leukaemia (Table 31). Leaving out the baseline (reference) exposure bands, there are 23 ORs of which 13 are positive, with 2 significant positives and no significant negatives. The p-values are 0.34 for the positives and 0.11 for the significant positives. Selection of high exposure results does not substantially change the picture. These studies do not give the same kind of message as the magnetic field results.
7. Comparison of reviews for adult brain cancer

CDHS again addresses the question of aggregation, citing 32 studies for adult brain cancer in Table 9.1.1, comprising 29 for occupational and 3 for residential exposures, and listing one representative result for each study (OR or other risk measure, with confidence limits). CDHS refers to a meta-analysis by Kheifets of the 29 occupational studies with overall OR of 1.2 (95% CI: 1.1 - 1.3) and to numbers of positive results and numbers with OR above 1.2. CDHS did not count numbers of significant results.

In Table 9.2.2 CDHS includes 7 additional studies to the 32 in Table 9.1.1 but gives confidence intervals for only 5 of them. One study combines residential and occupational exposure, and one is for electric fields (with a significant positive result). While CDHS discusses these additional 7 studies, they are not included in its aggregation (and make little overall difference to it). Our summary for the 32 cited studies is given in Table 4.

### Table 4. Aggregation of studies of adult brain cancer in CDHS (2002)

<table>
<thead>
<tr>
<th>CDHS/ brain (1 per study)</th>
<th>No. of ORs or risk measures</th>
<th>Positives</th>
<th>p-value for positives</th>
<th>Significant positives</th>
<th>p-value for sig-pos</th>
</tr>
</thead>
<tbody>
<tr>
<td>Residential occupational</td>
<td>3 29</td>
<td>2 23</td>
<td>0.5 0.001</td>
<td>0 6</td>
<td>1.0 7 x 10^-5</td>
</tr>
<tr>
<td>Total</td>
<td>32</td>
<td>25</td>
<td>0.001</td>
<td>6</td>
<td>0.0001</td>
</tr>
</tbody>
</table>

While these aggregations are not as strong as those for adult leukaemia, they are highly significant.

IARC selects 38 studies with brain cancer results for setting out in its main tables, of which 5 are residential (Table 26), 15 are occupational cohort studies (Table 29) and 18 are occupational case-control studies (Table 30). The respective numbers of results with risk measures and confidence intervals are 24, 32 and 53, that is 109 in all, but these include repetition of sub-type results in totals and include low-exposure as well as higher-exposure results from the same studies.

These studies include two (Spinelli 1995 and Ronneberg et al. 1999) which are for exposures to static magnetic fields. They would have been better excluded when assessing results for ELF (principally power-frequency) fields, as the two exposures are quite different. However, the CDHS lists also included one of these studies, Spinelli 1995, with results for both brain cancer (positive) and for leukaemia (negative). IARC includes these plus the negative results from Ronneberg et al. 1999. In treating CDHS and IARC comparably, these inappropriate results are here left in. The effect is slight, by way of diluting any overall findings.
Of the 109 crude results, 71 are positive and 16 are significant-positive. That would be highly significant under a null hypothesis for independent results. There are also 3 significant-negative results, each with the upper confidence limit just on 1.0. That would not be remarkable under a null hypothesis for 109 independent results \( (p = 0.51) \), but could be under a stronger alternative test hypothesis with a positive association.

One significant-negative result is for a low-exposure category residential study in Table 26; that study is declared for “nervous system” cancer rather than brain cancer \( per \ se \) but it is included in Table 26 which is for brain cancer. The other two significant-negatives are in Table 29 and are for males, while they are accompanied by non-significant positives for females; the selection criteria chose the more populous males, though if males and females were combined the significance would be lost. One significant-positive result was similar but the other way round, being just significant-positive for males alongside a non-significant negative for the less populous females. Some significant-positives listed for Cocco \( et \ al. \) 1999 in Table 30 may look suspicious at first sight, as three are reported as having OR as 1.2 \( (95\% \ CI = 1.1-1.2) \), which seem odd but could be accounted for by round-off from, for example, 1.17 \( (1.11-1.24) \) consistent with the usual log-normal model.

Applying our selection criteria obtains a more independent set of results, at most one per study, although as noted above it selects more populous male studies which would be partly countered by female studies. One study remained ambiguous and offered alternative opposite results of fairly equal weight (in Table 29, the Floderus \( et \ al. \) 1994, study of engine drivers or railway workers from the sixties or seventies); it was represented here as half positive and half negative. The result of selecting one result per study is summarised in Table 5.

<table>
<thead>
<tr>
<th>IARC/brain (1 per study)</th>
<th>No. of ORs</th>
<th>Positives</th>
<th>p-value for positives</th>
<th>Significant positives</th>
<th>p-value for sig-pos</th>
</tr>
</thead>
<tbody>
<tr>
<td>residential cohort</td>
<td>5</td>
<td>3</td>
<td>0.5</td>
<td>0</td>
<td>1.0</td>
</tr>
<tr>
<td>occupational case-control</td>
<td>15</td>
<td>9.5</td>
<td>0.15 - 0.3</td>
<td>3</td>
<td>0.0057</td>
</tr>
<tr>
<td>occupational</td>
<td>15</td>
<td>10</td>
<td>0.15</td>
<td>3</td>
<td>0.0057</td>
</tr>
<tr>
<td>total</td>
<td>35</td>
<td>22.5</td>
<td>0.04 - 0.09</td>
<td>6</td>
<td>0.0002</td>
</tr>
</tbody>
</table>

At this point the selection process has greatly weakened the aggregate evidence, largely because so many stronger results were in subsets. The selected evidence remains significant, if marginally so, and should not be dismissed, although it would not have the same statistical weight in assessment as that for adult leukaemia. In addition, the significance of the number of significant-positive results is tempered by the existence of three marginal significant-negatives in the crude data set, two of which survived selection of one result per study.
Applying the extra set of selection criteria loses even more strength of evidence, as so many of the brain cancer studies do not have an exposure assessment in terms of field strength. The result, in Table 6, has now lost significance, bearing in mind that one significant-negative result was also selected.

**Table 6**: Aggregation of studies of adult brain cancer in IARC (2002) on the basis of selection criteria to identify results with comparable exposures

<table>
<thead>
<tr>
<th>IARC / brain (select results)</th>
<th>No. of ORs</th>
<th>Positives</th>
<th>p-value for positives</th>
<th>Significant positives</th>
<th>p-value for sig-pos</th>
</tr>
</thead>
<tbody>
<tr>
<td>residential cohort</td>
<td>5</td>
<td>3</td>
<td>0.5</td>
<td>0</td>
<td>1.0</td>
</tr>
<tr>
<td>occupational</td>
<td>4</td>
<td>3</td>
<td>0.3</td>
<td>2</td>
<td>0.0036</td>
</tr>
<tr>
<td>case-control</td>
<td>5</td>
<td>3</td>
<td>0.5</td>
<td>0</td>
<td>1.0</td>
</tr>
<tr>
<td>total</td>
<td>14</td>
<td>9</td>
<td>0.2</td>
<td>2</td>
<td>0.047</td>
</tr>
</tbody>
</table>

8. **Comparison with evidence on childhood leukaemia**

The same approach to aggregation may be applied to the CDHS set of 19 studies for childhood leukaemia listed in Table 8.1.2. As with other health outcomes, CDHS applies its “sign test” and observes the 16 positive results out of 19, citing p = 0.0004 although our cumulative binomial calculation for 16 or more out of 19 gives p = 0.002. CDHS does not consider the number of significant results (3 out of 19; p = 0.01). There were no significant negative results and no results for OR or CLs truncated to 1.00.

IARC tables detailed results for childhood leukaemia for 14 childhood leukaemia studies in Tables 18, 19 and 23, comprising 10 residential exposure studies and 4 relating to use of domestic appliances. Applying the same processes as for adult leukaemia, we find out of 14 results (one per study) there are 13 positive and 3 significant-positive results, with p-values of 0.0009 and 0.005 respectively.

On this assessment of the value of the listed sets of studies, the evidence for adult leukaemia appears more significant than that for childhood leukaemia. However, we have not taken into account consistency of exposure type or measurement, nor of magnitude of apparent effect such as represented by ORs. CDHS refers to Wartenberg 2001 with a meta-analytic summary OR of 1.3 (1.0 - 1.7) for childhood leukaemia. This might reasonably be compared with the meta-analytic summaries cited for adult leukaemia of 1.2 (1.12 - 1.24) and for brain cancer of 1.2 (1.1 - 1.3) with reference to Kheifets et al. (1997a). There is not much difference between all three cancer groups at this level of meta-analysis.

The two more selective pooled analyses for childhood leukaemia, with ORs of 1.69 (1.25 - 2.29) for exposures above 0.3 µT by Greenland et al. (2000) and 2.00 (1.27 - 3.13) for exposures above 0.4 µT by Ahlbom et al. (2000) provide stronger results by focusing on fewer more coherent and comparable studies. Although the adult leukaemia and brain
cancer studies may be more disparate than those entirely residential studies pooled for childhood leukaemia, it would seem plausible that if they had better exposures measurements which could be used for selection, the result would also be to strengthen the overall finding.

9. Conclusions

There is a risk that review bodies, however august, may overlook the statistical weight of aggregate evidence in a collection of disparate studies which are individually inconclusive. It would be helpful in improving confidence in their reviews and assessment decisions if the issue of aggregation of disparate evidence could be seen to be addressed explicitly, preferably by a formal pooled analysis or meta-analysis to give an overall risk estimate, or if that is not available at least by the sort of significance analysis which we have demonstrated in this paper.

In aggregating evidence by the simple significance analysis we illustrate, when using the “sign test” (counting numbers of positive results), odds ratios reported as truncated at 1.0 or 1.00 etc. should be counted as half positive and not discounted. Counting numbers of significant results in this case gives stronger information than the simple sign test. If using the cumulative binomial distribution to assess the significance of numbers of positive results or of significant-positive results, it is important that the individual results are independent. We have suggested a set of selection criteria to produce at most one result per study for this purpose. However, one disadvantage of this approach is that a genuine raised risk in a particular cancer sub-type, could become lost in considering all subtypes in one group, for example all leukaemia, or all brain cancer.

The CDHS has addressed the aggregation of results, using the sign test and referring to external meta-analytic summaries, but it has not considered counts of significant results. The IARC review shows no evidence of having considered the aggregation of results other than subjectively. It has considered individual studies in detail and identified their shortcomings, but this has led to a tendency to fragment and dismiss evidence which is intrinsically highly significant.

Review bodies have a right to dismiss evidence on rational grounds, taking into account potential bias, confounding and methodological limitations as well as statistical strength, but should not do so without being seen also to take statistical aggregation into account.

The CDHS review, quite apart from its interesting and innovative qualitative Bayes approach, offers a useful complementary insight into the weight of epidemiological evidence in human studies. It adds a perspective which the mainstream international review bodies seem to have overlooked.

The differences in the conclusions of the IARC and CDHS reviews are not explained by differences in the sets of studies they considered. Their overlapping data sets on adult leukaemia, while surprisingly different in the studies included, both represent a highly significant body of aggregated evidence. In the case of brain cancer, the crude sets of data both appear highly significant in aggregate, though our selection criteria applied to the IARC data produced only a marginally significant aggregate result.
It is debatable whether the IARC classification system should be used to distinguish between specific diseases, since it seems to be designed to classify agents. It would be reasonable for the IARC classification to refer to evidence on childhood leukaemia in reaching a 2B classification. The additional evidence on adult leukaemia and brain cancer might then add further support, when taken in addition to childhood leukaemia.

By separating the evidence in humans for “all other cancers” (besides childhood leukaemia) and summarily classifying it as “inadequate” (section 5.5 page 338) IARC may be seen as effectively promoting a hypothesis that EMFs may be a cause of childhood leukaemia alone and of no other cancers. That is how we see policy makers interpreting it. We do not think this is rational for complex multi-causal diseases, especially bearing in mind evidence for possible systemic effects which could affect causation of several diseases. IARC does not seem to have addressed the question of compound hypotheses.

This exclusive attribution of the IARC 2B classification to childhood leukaemia has repercussions in precautionary policy, as manifest in the draft WHO Precautionary Framework (2006). Owing to its rarity, childhood leukaemia has relatively little impact on society and its avoidance relatively little benefit, compared with the substantially more prevalent adult leukaemia and brain cancer, as well as the other outcomes rated as 2B by CDHS.

An earlier review by the NIEHS 1999 had associated both adult and childhood leukaemia with a 2B classification, and both the IARC and CDHS reviews were informed by this. Given the extent and aggregate strength of the evidence for adult leukaemia, both in itself and in comparison with that for childhood leukaemia, it is difficult to see a clear division which would support an exclusive hypothesis of carcinogenicity of EMFs for childhood leukaemia but not for adult leukaemia.

10. Recommendations

The following recommendations are made for future reviews of EMF health effects

(i) IARC and other review bodies should incorporate expressly into their methodology some assessment of aggregate value of disparate evidence. Such assessment should not itself determine the overall assessment decision, but it is better to be aware of the nature of the aggregated data.

(ii) A focused pooled analysis should be undertaken for adult leukaemia to parallel, as far as possible, those of Ahlbom et al. and Greenland et al. for childhood leukaemia.

(iii) Advisory bodies considering precautionary policy relating to EMFs should take into account both the IARC and CDHS reviews, including the failure of IARC to demonstrate any assessment of aggregate value of evidence.

(iv) The WHO EMF team, in forming its Precautionary Framework, should expressly address the impact of possible health outcomes other than childhood leukaemia, noting especially their relatively high incidence compared with childhood leukaemia, and giving particular attention to the five outcomes classified by CDHS as corresponding to IARC class 2B.
References

Full references are not reproduced here for every study mentioned in the reviews, since references appear in the reviews themselves and their mention in this paper is concerned only with how they are counted in the reviews.


Rothman and Greenland, Modern Epidemiology, Lippincott, Williams & Wilkins, 2nd edition 1998

WHO Framework Guiding public health policy options in areas of scientific uncertainty with particular reference to EMFs. Draft for consultation, May 2006. The International EMF Project Radiation and Environmental Health Unit World Health Organization Email: emfproject@who.int